论文部分内容阅读
本研究观察白血病和卵巢癌亲代及耐药细胞系中端粒酶活性及细胞外调节蛋白激酶 (extracelluarregula tedproteinkinasesERK)磷酸化蛋白表达水平的变化 ,探讨端粒酶与ERK在白血病及卵巢癌耐药中的作用。采用MTT法评价白血病和卵巢癌亲代和耐药细胞系对HRT或DDP的敏感性 ,用流式细胞术分析这两种细胞系间细胞周期分布的差别 ,用端粒酶重复扩增技术 (TRAP)、生物发光分析法定量和定性检测端粒酶活性及用Westernblot检测法检测磷酸化ERK1 和ERK2 蛋白的表达水平。结果表明 :白血病和卵巢癌耐药细胞系处于G0 G1 期的细胞比例增加 ,端粒酶活性和磷酸化ERK1 2 蛋白表达水平耐药细胞系较亲代细胞系高。结论 :耐药细胞系G0 G1期细胞比例增加可能是细胞产生耐药的一种标志。白血病和卵巢癌细胞系耐药的产生可能与端粒酶活性和磷酸化ERK1 2 蛋白表达水平的增高有关。
This study was to observe the changes of telomerase activity and phosphorylated protein expression of extracellular regulatory protein kinase (ERK) in the leukemia and ovarian cancer parental and drug resistant cell lines and to explore the relationship between telomerase and ERK in drug resistance of leukemia and ovarian cancer Role. The susceptibility of HRT or DDP to parental and drug-resistant cell lines of leukemia and ovarian cancer was assessed by MTT assay. The differences in cell cycle distribution between the two cell lines were analyzed by flow cytometry. The TRAP ), The bioluminescence assay was used to detect the telomerase activity quantitatively and qualitatively, and the phosphorylation levels of ERK1 and ERK2 protein were detected by Western blot. The results showed that the proportion of cells in the G0 / G1 phase of leukemia and ovarian cancer resistant cell lines increased, and telomerase activity and phosphorylated ERK1 2 protein expression levels were higher in drug-resistant cell lines than in parental cell lines. Conclusion: Increasing the proportion of cells in the G0 G1 phase of drug-resistant cell lines may be a marker of cell resistance. The development of drug resistance in leukemia and ovarian cancer cell lines may be related to the increase of telomerase activity and phosphorylated ERK1 2 protein expression.